98 related articles for article (PubMed ID: 26796506)
1. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor.
Argani P; Lee J; Netto GJ; Zheng G; Tseh-Lin M; Park BH
Am J Surg Pathol; 2016 May; 40(5):719-22. PubMed ID: 26796506
[No Abstract] [Full Text] [Related]
2. BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors.
Marsden L; Jennings LJ; Gadd S; Yu M; Perlman EJ; Cajaiba MM
Hum Pathol; 2017 Feb; 60():32-36. PubMed ID: 27769870
[TBL] [Abstract][Full Text] [Related]
3. Application of BRAF V600E mutation analysis for the diagnosis of metanephric adenofibroma.
Mangray S; Breese V; Jackson CL; Lombardo K; Taliano R; Resnick M; Yakirevich E
Am J Surg Pathol; 2015 Sep; 39(9):1301-4. PubMed ID: 26274032
[No Abstract] [Full Text] [Related]
4. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.
Udager AM; Pan J; Magers MJ; Palapattu GS; Morgan TM; Montgomery JS; Weizer AZ; Hafez KS; Miller DC; Wolf JS; McHugh JB; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Am J Surg Pathol; 2015 Apr; 39(4):549-57. PubMed ID: 25602792
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutations in pediatric metanephric tumors.
Chami R; Yin M; Marrano P; Teerapakpinyo C; Shuangshoti S; Thorner PS
Hum Pathol; 2015 Aug; 46(8):1153-61. PubMed ID: 26014474
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in metanephric adenoma of the kidney.
Choueiri TK; Cheville J; Palescandolo E; Fay AP; Kantoff PW; Atkins MB; McKenney JK; Brown V; Lampron ME; Zhou M; Hirsch MS; Signoretti S
Eur Urol; 2012 Nov; 62(5):917-22. PubMed ID: 22727996
[TBL] [Abstract][Full Text] [Related]
7. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
8. Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.
Wobker SE; Matoso A; Pratilas CA; Mangray S; Zheng G; Lin MT; Debeljak M; Epstein JI; Argani P
Am J Surg Pathol; 2019 Sep; 43(9):1157-1169. PubMed ID: 31192863
[TBL] [Abstract][Full Text] [Related]
9. BRAF and KIT somatic mutations are present in amelanotic melanoma.
Massi D; Pinzani P; Simi L; Salvianti F; De Giorgi V; Pizzichetta MA; Mirri F; Steffan A; Orlando C; Santucci M; Canzonieri V
Melanoma Res; 2013 Oct; 23(5):414-9. PubMed ID: 23938765
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
11. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
12. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
13. Thyroid-like follicular carcinoma of the kidney: The mutational profiling reveals a BRAF wild type status.
Fanelli GN; Fassan M; Dal Moro F; Soligo M; Munari G; Zattoni F; Gardiman MP; Prayer-Galetti T
Pathol Res Pract; 2019 Sep; 215(9):152532. PubMed ID: 31345592
[No Abstract] [Full Text] [Related]
14. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
15. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
17. KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas.
Catic A; Kurtovic-Kozaric A; Sophian A; Mazur L; Skenderi F; Hes O; Rohan S; Rakheja D; Kogan J; Pins MR
BMC Med Genet; 2020 Oct; 21(1):202. PubMed ID: 33046021
[TBL] [Abstract][Full Text] [Related]
18. Adult classical glioblastoma with a BRAF V600E mutation.
Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
[TBL] [Abstract][Full Text] [Related]
19. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
20. Metanephric stromal tumor in an adult with PDGFRA mutation: a case report.
Guo S; Qian H; Zhu H; Yang Y; Yang X; Sun H
Diagn Pathol; 2023 Jul; 18(1):83. PubMed ID: 37454137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
